Literature DB >> 12588332

A new method for normalized interpretation of antimicrobial resistance from disk test results for comparative purposes.

G Kronvall1, G Kahlmeter, E Myhre, M F Galas.   

Abstract

OBJECTIVE: To evaluate a calibration method for disk diffusion antibiotic susceptibility tests, using zone diameter values generated in the individual laboratory as the internal calibrator for combinations of antibiotic and bacterial species.
METHODS: The high-zone side of zone histogram distributions was first analyzed by moving averages to determine the peak position of the susceptible population. The accumulated percentages of isolates for the high zone diameter values were calculated and converted into probit values. The normal distribution of the ideal population of susceptible strains was then determined by using the least-squares method for probit values against zone diameters, and the ideal population was thereby defined, including mean and standard deviation. Zone diameter values were obtained from laboratories at the Karolinska Hospital (KS) and Växjö Hospital (VX), and from two laboratories (LabA, LabB) in Argentina. The method relies on well standardized disk tests, but is independent of differences in MIC limits and zone breakpoints, and does not require the use of reference strains. Resistance was tentatively set at below 3 SD from the calculated, ideal mean zone diameter of the susceptible population.
RESULTS: The method, called normalized interpretation of antimicrobial resistance, was tested on results from the KS and VX clinical microbiology laboratories, using the disk diffusion method for antimicrobial susceptibility tests, and for two bacterial species, Staphylococcus aureus and Escherichia coli. In total, 114 217 test results were included for the clinical isolates, and 3582 test results for control strains. The methodology at KS and VX followed the standard of the Swedish Reference Group for Antibiotics (SRGA). Zone diameter histograms for control strains were first analyzed to validate the procedure, and a comparison of actual means with the calculated means showed a correlation coefficient of r = 0.998. Results for clinical isolates at the two laboratories showed an excellent agreement for 54 of 57 combinations of antibiotic and bacterial species between normalized interpretations and the interpretations given by the laboratories. There were difficulties with E. coli and mecillinam, and S. aureus and tetracycline and rifampicin. The method was also tested on results from two laboratories using the NCCLS standard, and preliminary results showed very good agreement with quality-controlled laboratory interpretations.
CONCLUSIONS: The normalized resistance interpretation offers a new approach to comparative surveillance studies whereby the inhibition zone diameter results from disk tests in clinical laboratories can be used for calibration of the test.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12588332     DOI: 10.1046/j.1469-0691.2003.00546.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  17 in total

1.  Normalized resistance interpretation as a tool for establishing epidemiological MIC susceptibility breakpoints.

Authors:  Göran Kronvall
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

Review 2.  Setting and revising antibacterial susceptibility breakpoints.

Authors:  John Turnidge; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

3.  The Resistant-Population Cutoff (RCOFF): a New Concept for Improved Characterization of Antimicrobial Susceptibility Patterns of Non-Wild-Type Bacterial Populations.

Authors:  Giorgia Valsesia; Michael Hombach; Florian P Maurer; Patrice Courvalin; Malgorzata Roos; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2015-03-11       Impact factor: 5.948

4.  Validation of antibiotic susceptibility testing guidelines in a routine clinical microbiology laboratory exemplifies general key challenges in setting clinical breakpoints.

Authors:  Michael Hombach; Patrice Courvalin; Erik C Böttger
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

5.  Antibiotic-Resistant Escherichia coli in Migratory Birds Inhabiting Remote Alaska.

Authors:  Andrew M Ramey; Jorge Hernandez; Veronica Tyrlöv; Brian D Uher-Koch; Joel A Schmutz; Clara Atterby; Josef D Järhult; Jonas Bonnedahl
Journal:  Ecohealth       Date:  2017-12-11       Impact factor: 3.184

6.  A statistical approach for determination of disk diffusion-based cutoff values for systematic characterization of wild-type and non-wild-type bacterial populations in antimicrobial susceptibility testing.

Authors:  Giorgia Valsesia; Malgorzata Roos; Erik C Böttger; Michael Hombach
Journal:  J Clin Microbiol       Date:  2015-03-11       Impact factor: 5.948

7.  Biological costs and mechanisms of fosfomycin resistance in Escherichia coli.

Authors:  Annika I Nilsson; Otto G Berg; Olle Aspevall; Gunnar Kahlmeter; Dan I Andersson
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

8.  Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.

Authors:  Lorna E T Stearne; Wil H F Goessens; Johan W Mouton; Inge C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

9.  Phenotypic and Molecular Traits of Staphylococcus coagulans Associated with Canine Skin Infections in Portugal.

Authors:  Sofia Santos Costa; Valéria Oliveira; Maria Serrano; Constança Pomba; Isabel Couto
Journal:  Antibiotics (Basel)       Date:  2021-05-02

10.  Characterization and comparison of extended-spectrum β-lactamase (ESBL) resistance genotypes and population structure of Escherichia coli isolated from Franklin's gulls (Leucophaeus pipixcan) and humans in Chile.

Authors:  Jorge Hernandez; Anders Johansson; Johan Stedt; Stina Bengtsson; Aleksandra Porczak; Susanne Granholm; Daniel González-Acuña; Björn Olsen; Jonas Bonnedahl; Mirva Drobni
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.